Research Resources Milestones
3.A-3.I, 4.A-4.AA, 14.A-14.P, 15.A
No filters selected
ID
Title
Status
3.A
Data Sharing: Data accessibility
Provide resources to make datasets from existing and legacy clinical research studies on AD and related dementias widely accessible…
Status
In Progress
3.B
Data Sharing: Interoperability
Provide support to establish/improve the interoperability among relevant biomedical data repositories.…
Status
In Progress
3.C
Data Sharing: Reporting and reproducibility
Increase transparency in reporting and reproducibility of research findings by incentivizing and enforcing rapid sharing…
Status
In Progress
3.D
Data Sharing: Access to clinical trial data/samples
Enable access to data and associated biosamples and biomarkers from completed, ongoing and future, federally and privately funded clinical trials...
Status
In Progress
3.E
Data Sharing: Tool sharing
Accelerate independent evaluation of research findings by mandating the open distribution of publicly and privately/philanthropically funded computational and experimental research tools...
Status
In Progress
3.F
Data Sharing: Computational infrastructure
Democratize the use of large scale molecular and clinical data by building computational infrastructure for sustainable data storage...
Status
Achieved
3.G
FTD Basic and Clinical Research: Data and research infrastructure
Develop data and resource infrastructures to support management and collaborative analysis of diverse resources from FTD basic science and clinical studies.
Status
Achieved
3.H
Data Sharing and Reproducibility: Systems for increasing research rigor
Improve rigor, reproducibility, and translatability of discovery research.
Status
In Progress
3.I
MED: Best practices for ADRD research data sharing
Best practices for ADRD research data sharing
Status
In Progress
4.A
Translational Capabilities: Next-generation animal models
Support the development of the next generation of animal models based on the current understanding of genetic and environmental risk and protective factors for AD and related dementias…
Status
Achieved
4.B
Translational Capabilities: Characterization of animal models
Create infrastructure/resources for extensive characterization of existing and new animal models…
Status
Achieved
4.C
Translational Capabilities: Animal models with higher predictive validity
Continue to develop animal models with higher predictive validity for use in preclinical drug development…
Status
In Progress
4.D
Translational Capabilities: Expand biorepository infrastructure
Expand biorepository infrastructure to enable storage and rapid distribution of clinical data and biosamples…
Status
In Progress
4.E
Translational Capabilities: Isolation of neural and glial cells
Support the development of standardized, cost-effective, high throughput methods…
Status
In Progress
4.F
Translational Capabilities: Improved iPSC protocols
Develop improved iPSC protocols for all relevant cell types and human-based organoid model systems...
Status
In Progress
4.G
Translational Capabilities: Applying principles of pharmacology
Support quantitative systems pharmacology approaches that couple biological network and pathway analyses…
Status
In Progress
4.H
Translational Capabilities: Expedite application review
Institute an expedited review track for applications focused on drug discovery, preclinical, and clinical drug development...
Status
To Be Initiated
4.I
Translational Capabilities: National IRB
Create a National IRB.
Status
Achieved
4.J
Translational Capabilities: Training programs
Expand existing and create new integrative training programs for junior neuroscience, behavioral and social science researchers...
Status
In Progress
4.K
Translational Capabilities: Expanding genetics efforts and data sharing
Leverage the power of human genetics to enable precision medicine research for AD...
Status
In Progress
4.L
Translational Capabilities: Single cell molecular profiling
Support standardized, single cell molecular profiling (genomic, proteomic, metabolomic)...
Status
In Progress
4.M
Translational Capabilities: Genome-scale metabolic models
Support the development of genome-scale metabolic models to capture the heterogeneity of metabolic transitions...
Status
Achieved
4.N
Translational Capabilities: High-throughput technologies
Provide support for high-cost capital equipment/core facilities and staff training to make high-throughput technologies...
Status
To Be Initiated
4.O
Translational Capabilities: Target enabling tools
De-risk novel candidate targets by supporting the development of high quality, open source, target enabling tools...
Status
Achieved
4.P
FTD Clinical Research: International trial network
Create an international FTD clinical trial network.
Status
Achieved
4.Q
FTD Basic Research: Establish new animal and cellular models
Develop better FTLD in vivo and cell-based model systems.
Status
In Progress
4.R
VCID Research: Establish new experimental models and imaging methods
Develop models that: reproduce small vessel disease; are relevant to VCID and AD; address white and grey matter VCID; or include genetic and acquired VCID. Verify models, including via imaging.
Status
In Progress
4.S
Health Equity: Facilitate health disparities research training
Improve and increase training, including for individuals who are members of under-represented populations, and of different career levels of scholars who conduct health disparities research in AD/ADRD.
Status
In Progress
4.T
VCID: Conduct basic research informed by findings from human studies
Use data and other resources from large-scale clinical research and trials to test hypothesized mechanisms of human VCID in basic science models.
Status
In Progress
4.U
VCID: Conduct clinical research informed by basic research findings
Incorporate VCID findings from basic science into the design of clinical research and trials targeting VCID-relevant cognitive impairment and dementia.
Status
In Progress
4.V
TDP-43 in AD/ADRD: Develop animal models
Build new animal models to advance knowledge about TDP-43 pathology in common dementias, capitalizing on lessons learned from animal models in FTLD/ALS, AD and other diseases.
Status
In Progress
4.W
Translational Capabilities: Open drug development
Enable open drug development to generate innovative new medicines that are priced fairly for all.
Status
To Be Initiated
4.X
Translational Capabilities: Translational and basic research network interactions
Create opportunities and avenues for closer interaction between researchers developing new INDs and researchers supported through NIA's enabling infrastructure programs involved in developing data resources, translational tools and new mechanistic insight
Status
In Progress
4.Y
Translational Capabilities: Seamless phase I to phase II transition
Evaluate and update current trial funding models to ensure the ability to test novel first-in-class therapeutics in the context of the full range of expenses and time frames required for robust evaluation and sharing.
Status
In Progress
4.Z
Health Equity: Career development
Promote career development of biomedical, behavioral, and social scientists conducting AD/ADRD health equity research.
Status
In Progress
4.AA
MED-COVID-19: Building research infrastructure
Impact of COVID-19 on AD/ADRD: Building research infrastructure
Status
In Progress
14.A
Public Private Partnerships: Partnerships to accelerate therapy development
Convene an advisory meeting focused on facilitating public-private partnerships aimed at accelerating the development and test of effective therapies for AD treatment and prevention...
Status
Achieved
14.B
Public Private Partnerships: Convene meetings to accelerate drug development
Convene meetings of the working groups for (i) Rapid Data Sharing and Analysis, (ii) Enabling Bidirectional Translation in AD drug development, (iii) Eliminating IP barriers for Target Validation...
Status
Achieved
14.C
Public Private Partnerships: Support early career investigators
Develop partnerships to support novel/disruptive science that would incentivize students and early-career investigators to adopt a collaborative approach...
Status
In Progress
14.D
Public Private Partnerships: Expand the pre-competitive space
Develop partnerships that expand the precompetitive space through clinical proof of concept mechanism to accelerate translational learning...
Status
To Be Initiated
14.E
Public Private Partnerships: Data sharing
Develop a partnership among key stakeholders to implement the sharing of all data and biosamples from preclinical and clinical studies ...
Status
Achieved
14.F
Public Private Partnerships: Consensus nomenclature
Update consensus on AD/ADRD nomenclature necessary to identify target populations for intervention research...
Status
In Progress
14.G
Public Private Partnerships: Eliminating barriers to sharing, integrating, and reuse of data
Convene an advisory meeting of relevant stakeholders to develop a consensus regarding eliminating barriers to sharing, integrating, and reuse of data...
Status
In Progress
14.H
Public Private Partnerships: Improve institutional practices
Alter institutional practices that impede team science and data sharing in academia
Status
In Progress
14.I
Public Private Partnerships: Best practices for biosamples
Develop and disseminate best practices for the collection, processing, and multi-omics molecular profiling of human and animal model biosamples.
Status
In Progress
14.J
Public Private Partnerships: Advance rational drug repositioning and combination therapy
Convene an advisory meeting of experts from the pharmaceutical industry, government, academia, the FDA, and the non-profit sector...
Status
In Progress
14.K
Community Engagement: Facilitate NIH-NGO interactions on ADRD
Establish effective communication between NIH and NGOs
Status
Achieved
14.L
AD/ADRD Nomenclature: Research, clinical practice, and stakeholder working groups
Organize a working group of stakeholders, including health disparities communities, to develop more consistent nomenclature in dementia research and care.
Status
Achieved
14.M
Health Equity: Health disparities task force
Generate an AD/ADRD health disparities task force
Status
Achieved
14.N
AD/ADRD Nomenclature: Standardized research, clinical practice, and stakeholder nomenclature
Integrate and refine recommendations from working groups into standardized, acceptable and accurate nomenclature that works across the spectrum of stakeholders.
Status
In Progress
14.O
Partnerships: NIA/NIH/FDA collaboration
Collaboration to advance biomarkers and therapy development for AD/ADRD
Status
In Progress
14.P
Partnerships: Global data sharing
Large international collaborations aimed at overcoming barriers to sharing of human data
Status
To Be Initiated
15.A
Portfolio Analysis: AD/ADRD research ontology, public database
Develop a common Alzheimer’s disease research ontology...
Status
In Progress